Drug Profile


Alternative Names: 1-deoxynojirimycin hydrochloride; AT-2220; AT2220-ERT combo therapy; AT2220-IV; Duvoglustat HCl; duvoglustat hydrochloride; duvoglustat-ERT combo therapy; HGT-3510

Latest Information Update: 09 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amicus Therapeutics
  • Class Alkaloids; Imino pyranoses; Pharmacological chaperones; Small molecules
  • Mechanism of Action Alpha-glucosidase stimulants; Protein folding stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glycogen storage disease type II

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 09 Aug 2015 Clinical development of duvoglustat is ongoing
  • 14 Feb 2013 Amicus Therapeutics plans a repeat-dose trial for Glycogen storage disease type II (IV formulation) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top